FDA approves Abbott’s Creon for infants

Abbott announced Tuesday that the FDA approved an infant-specific version of Creon (pancrelipase) for the treatment of exocrine pancreatic insufficiency due to cystic fibrosis. “This approval means that Creon will now be available in four dosing options…providing improved dosing titration options and flexibility into adulthood,” said Eugene Sun, head of global pharmaceutical development.

The new lipase capsule will allow infants to receive a more precise dose of the medication, whereas previously a smaller dose of the pancreatic enzyme replacement therapy was obtained by measuring out a portion from a larger-dose capsule.